Company / SG&A Expense
Xenon Pharmaceuticals Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$79.6M
FY2025
5-year range
$22.0M / $79.6M
FY2021-FY2025
Trend
+15.6%
vs FY2024
Sector context
#126 of 213
Health Care
What the data says
At $80M, Xenon Pharmaceuticals Inc.'s sg&a expense ranks #88 of 213 in the Health Care sector. SG&A Expense has increased for 7 consecutive years, from $8M in FY2018 to $80M in FY2025.
Based on SEC 10-K filings.
$80M in FY2025 with a 5-year CAGR of +43.8%.
Increased from $47M to $80M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +34.4%
- 5-Year CAGR
- +43.8%
- 10-Year CAGR
- -
Sector benchmark
#88 of 213 in Health CareTop 41% of 213This company $79.6M Sector average $722.3M
▼
-89.0% below sector average
Key checks
Key Insights
- Xenon Pharmaceuticals Inc.'s sg&a expense has grown for 7 consecutive years.
- 5-year CAGR of +43.8%, indicating consistent growth.
- In FY2025, sg&a expense increased 15.6% year-over-year.
- Ranks #126 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.51 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $79.6M | +15.6% |
| FY2024 | $68.9M | +48.0% |
| FY2023 | $46.5M | +41.9% |
| FY2022 | $32.8M | +49.4% |
| FY2021 | $22.0M | +69.7% |
| FY2020 | $12.9M | +19.8% |
| FY2019 | $10.8M | +28.5% |
| FY2018 | $8.4M | -14.1% |
| FY2017 | $9.8M | +44.1% |
| FY2016 | $6.8M | -30.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026